| Invasive Urothelial Carcinoma studied in …STUDIED_INderived10 of 48show all (up to 200) |
|---|
| → studied in | NCT06770582Phase 2 · recruiting Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial · condition mapped ONTOLOGY_EXACT · 48 trials mapped (32 active) | — | — | Non-Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 48 trials mapped (32 active) | — | — | Invasive Bladder Giant Cell Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06605404recruiting Pan-tumor MRD Study · condition mapped ONTOLOGY_EXACT · 48 trials mapped (32 active) | — | — | Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07061964Phase 2 · recruiting Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial · condition mapped ONTOLOGY_EXACT · 48 trials mapped (32 active) | — | — | Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05987241Phase 2/Phase 3 · recruiting Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · condition mapped ONTOLOGY_EXACT · 48 trials mapped (32 active) | — | — | Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07332351Phase 2 · not yet recruiting Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial · condition mapped ONTOLOGY_EXACT · 48 trials mapped (32 active) | — | — | Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07667335Phase 1/Phase 2 · recruiting Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer · condition mapped CURATED_BROADER · 48 trials mapped (32 active) | — | — | Invasive Bladder Giant Cell Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07822373Phase 2 · not yet recruiting A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer · condition mapped ONTOLOGY_EXACT · 48 trials mapped (32 active) | — | — | Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02812420early Phase 1 · active not recruiting Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · condition mapped ALIAS · 48 trials mapped (32 active) | — | — | Invasive Bladder Sarcomatoid Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06503614Phase 2 · recruiting A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer · condition mapped ONTOLOGY_EXACT · 48 trials mapped (32 active) | — | — | Non-Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |